Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

http://www.wikidata.org/entity/Q34615704

about

Appraisal of immunoglobulin free light chain as a marker of response Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system Deep Response in Multiple Myeloma: A Critical Review Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival The evolving use of serum free light chain assays in haematology.C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia.Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma.Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma Prognostic significance of serum free light chains in chronic lymphocytic leukemia.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.Serum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Renal failure in multiple myeloma: a medical emergency.Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.Risk Stratification in Multiple Myeloma.Standardisation of minimal residual disease in multiple myeloma.Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma.Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma.Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.Diagnostic dilemma in a case of osteolytic lesions.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.Screening panels for monoclonal gammopathies: time to change Further stratification of patients with multiple myeloma by International Staging System in combination with ratio of serum free κ to λ light chains.A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains.Disease spectrum of abnormal serum free light chain ratio and its diagnostic significance.Adjuvant immunotherapy of dendritic cells and cytokine-induced killer cells is safe and enhances chemotherapy efficacy for multiple myeloma in China: a meta-analysis of clinical trials.Minimal residual disease in multiple myeloma: Benefits of flow cytometry.Utilisation of sFLC assays - how well do we comply with guidelines?Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents.

P2860

Q24624398-90E46605-0048-43E7-8C0A-254BE6A11EF1 Q24650785-7B8CC289-4D67-43E9-A390-7CF3A90B4B5B Q24653434-2ED0798A-F33D-4A36-91E7-16F156B6C9CC Q26771228-07C866AF-D974-4747-B010-A0102B80325E Q33371085-1D7E9D64-D3F8-454B-9658-BD58A23AD261 Q33831838-19ACF202-E26C-4C63-812B-60978F021084 Q34758218-610A4D53-2198-4EFD-8C8E-9D73FF4A5DD9 Q34936088-0975E365-5E68-4F3A-9AC1-6F135FCBFBA0 Q35847877-D62B3747-77AA-4165-AFA6-709179A684B0 Q36081225-8B3E9977-99A6-4C63-8519-454AF447A054 Q36137449-6FC2BA7E-D41D-478C-AA29-46941A883451 Q36205711-6843924E-87DC-4AA8-925C-835300DC3F67 Q36444477-5BFE53CD-0324-4AF5-BEF3-481523FC6EE2 Q36525219-3EF64513-BFC2-4379-A4FF-193A85B5D543 Q36525224-0E3ACCF4-880C-4B74-86F5-3555BC5A7BE3 Q36572310-BBC5BDA8-673A-4D1B-9540-420FE2A5DEAD Q37316098-AE8B1ABD-9EDC-495D-866B-40516AF37C91 Q37528072-6765098F-0505-412D-9949-7E06D2C47008 Q37701511-DDA99B02-A140-4025-8D67-FF47F0F86D4B Q37821496-2D8072BD-45BD-4722-B6BC-26C496AB957F Q37845643-C6DE523F-60F1-4385-99F5-A733EDA3EB0B Q38010146-8EEB1A96-09A1-46A3-9A16-4705C55EF604 Q38168869-ED7ACEC1-B038-4B52-BA48-3D88AA8BEF9D Q38736249-5F6C21AC-911C-4237-A285-90839CB0B7E1 Q39410899-CB4E27FE-410F-4CD8-B1D0-12556DA88E9D Q39491956-A557BB9E-5E43-43B9-834D-1C79709C9510 Q39531260-4B0354EF-CDA2-41D0-B4E8-F8BA27DA12CB Q39932145-E486A8DC-12FA-4DD3-BA25-BDF9260E59BF Q40215314-AE5519DC-7E12-4300-9187-363EFD459960 Q40368431-878A1382-C8A7-49AF-95E2-EF1E2C3B59BC Q40563598-7BE39E2B-6F4F-404C-84C5-73AA360A06EA Q42098619-E22FE46C-F9D8-44EA-95ED-4E4ECE5337F5 Q44944338-B28C6423-A32D-4F50-A2AE-B773AE47222C Q45918889-C381583D-C810-4929-9B6D-9FBC40EA9B71 Q47098001-37228EA0-1360-423F-AC8F-6FAABD13F141 Q47147912-323A8725-8C3D-4647-BD96-B73E33767BB3 Q47744241-BF63743D-5CFA-4257-B6A3-E91C8B72218E Q50898321-D605F88C-4642-450D-AB1D-0442F2A8933C Q53081939-33887586-E581-4A78-80B6-96D5FB351721 Q53087672-9AD3E1AF-7A59-4ED3-898F-B4A7A7DF3FE3

P2860

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

http://www.wikidata.org/entity/Q34615704

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@ast

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@en

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@nl

type

label

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@ast

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@en

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@nl

prefLabel

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@ast

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@en

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@nl

P1433

Q34615704-E26C6EEE-58DF-42AB-990D-3575CBF40DEE

P1476

Q34615704-81359881-47AE-43E5-8978-52A4EE729968

P2093

Q34615704-0DBAA52C-780B-4939-A899-8D08C8E09D1D

Q34615704-149C2A26-D762-4944-A68D-65F668E52B74

Q34615704-2680A201-8829-4302-A140-19A2D6B73F0C

Q34615704-281AB086-2731-4C29-8C91-3792BD22E68F

Q34615704-428A6728-292C-4670-9A1F-3EF9F74D22C2

Q34615704-434CD8D5-68E2-4EDF-B9D4-32FCFE7A53B8

Q34615704-54A36261-6D67-44A1-AE5F-3669FFEFB361

Q34615704-6F8D4222-9F3A-4AC0-9011-15E6E4DEAF43

Q34615704-AC7DB0C9-81AB-445F-887B-ECC20FD7DB0A

Q34615704-B0F5E4C4-3229-42C8-B09A-E99CF2D0ED2C

P2860

Q34615704-1DE44BF2-A152-4367-990E-7530C40BE4C0

Q34615704-42DDC297-65CB-4B4B-8E56-AA009F71F9C9

Q34615704-4C23D4A9-7233-4B9B-A716-7F99FF80412F

Q34615704-63F6A1A9-FCC6-45FD-80B3-A7DB8B5CBD84

Q34615704-78BE6AB8-7A36-4DCC-AF8C-97254807EFF5

Q34615704-BEF6DF72-9C84-40E3-8228-A2ED76A5D51A

Q34615704-CABB0B40-C820-4342-88DA-F63A82751692

Q34615704-D2DE3C01-6A77-46B5-B12B-70486DFB7F99

Q34615704-F28D9507-7F83-4ED2-B3C0-F7A9E54E7881

Q34615704-FB51743B-1AB4-44AC-BC3A-D3E7B1F09E3C

P304

Q34615704-03C2F6C4-BC73-4C43-8616-AB1AA1900CAC

P31

Q34615704-78506CA0-96C1-4A6A-8AA1-7695D243C574

P356

Q34615704-62856EB5-CE42-40C2-A7FD-A3628D440720

P407

Q34615704-7167361A-50F9-4C8C-B239-F9CAE747AE84

P433

Q34615704-487EBF7E-70AF-4378-9C9B-3B2F4EEBC0C9

P478

Q34615704-0669DCC5-100C-4981-BCB5-1004F02ADCD9

P577

Q34615704-85DABC3D-E68B-478A-899F-1420D73889C7

P5875

Q34615704-7EE6FC28-FD0B-402A-B14A-5528EEEE1EE6

P698

Q34615704-993040A8-EEB0-4755-A90B-E788C9096569

P356

J.1365-2141.2007.06561.X

P1433

British Journal of Haematology

P1476

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

@en

P2093

Argiroula Papadogiannis

http://www.w3.org/2001/XMLSchema#string

Christina Kalpadakis

http://www.w3.org/2001/XMLSchema#string

Elias Kyriakou

http://www.w3.org/2001/XMLSchema#string

Evangelia M Dimitriadou

http://www.w3.org/2001/XMLSchema#string

Gerassimos A Pangalis

http://www.w3.org/2001/XMLSchema#string

Maria Dimou

http://www.w3.org/2001/XMLSchema#string

Maria K Angelopoulou

http://www.w3.org/2001/XMLSchema#string

Maria N Dimopoulou

http://www.w3.org/2001/XMLSchema#string

Marie-Christine Kyrtsonis

http://www.w3.org/2001/XMLSchema#string

Marina P Siakantaris

http://www.w3.org/2001/XMLSchema#string

P2860

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

Immunoglobulin free light chains and solitary plasmacytoma of bone

Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3.

Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma.

Serum test for assessment of patients with Bence Jones myeloma.

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.

International staging system for multiple myeloma.

International uniform response criteria for multiple myeloma.

Serum free light chains for monitoring multiple myeloma.

Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials

P304

240-243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2007.06561.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6414414

http://www.w3.org/2001/XMLSchema#string

P698

17408464

http://www.w3.org/2001/XMLSchema#string